Cargando…

Characterization of the Antibody and Interferon-Gamma Release Response after a Second COVID-19 Booster Vaccination

The emergence of SARS-CoV-2 Omicron subvariants prompted countries to call for accelerated booster vaccinations to limit disease and transmission. Here, we characterized correlates of protection over time after the second booster or after Omicron BA.1 infection comparing variants of concern (VOCs)....

Descripción completa

Detalles Bibliográficos
Autores principales: Grikscheit, Katharina, Rabenau, Holger F., Ghodratian, Zahra, Widera, Marek, Wilhelm, Alexander, Toptan Grabmair, Tuna, Hoehl, Sebastian, Layer, Emily, Helfritz, Fabian, Ciesek, Sandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323888/
https://www.ncbi.nlm.nih.gov/pubmed/35891326
http://dx.doi.org/10.3390/vaccines10071163
_version_ 1784756668644458496
author Grikscheit, Katharina
Rabenau, Holger F.
Ghodratian, Zahra
Widera, Marek
Wilhelm, Alexander
Toptan Grabmair, Tuna
Hoehl, Sebastian
Layer, Emily
Helfritz, Fabian
Ciesek, Sandra
author_facet Grikscheit, Katharina
Rabenau, Holger F.
Ghodratian, Zahra
Widera, Marek
Wilhelm, Alexander
Toptan Grabmair, Tuna
Hoehl, Sebastian
Layer, Emily
Helfritz, Fabian
Ciesek, Sandra
author_sort Grikscheit, Katharina
collection PubMed
description The emergence of SARS-CoV-2 Omicron subvariants prompted countries to call for accelerated booster vaccinations to limit disease and transmission. Here, we characterized correlates of protection over time after the second booster or after Omicron BA.1 infection comparing variants of concern (VOCs). Sera from subjects before and two and seven weeks after the second booster or after Omicron infection were examined for the level of Spike receptor-binding-domain (RBD)-specific antibodies. Furthermore, neutralizing antibodies (nABs) were characterized in in vitro neutralization assays comparing the variants of concern Alpha, Beta, Delta, and Omicron BA.1 and BA.2 against the ancestral strain B.1. Here, the second booster resulted in an increase in anti-RBD-IgG-antibodies, remaining nearly constant over time, accompanied by an increase in nABs against B.1 and the VOCs Alpha, Beta, Delta, and Omicron BA.1 and BA.2. However, compared to B.1, the neutralizing capacity against the Omicron subvariants remained low and was limited after the second booster vaccination. This indicates that antibody-mediated protection against infection with this VOC is unlikely, as evidenced by the fact that three individuals of our study cohort became infected with Omicron BA.1 after the second booster. T cell activation was measured by interferon-gamma release assays in a subgroup of subjects and was increased in all subjects tested after the second booster vaccination, correlating with the amount of Spike-specific antibodies. In subjects with Omicron BA.1 breakthrough infection, a significant increase in nABs to all VOCs studied was observed independently of booster vaccinations. Taken together, our data indicate that a second booster or Omicron BA.1 infection mediate a substantial increase in anti-Spike IgG antibodies; however, infection with Omicron BA.1 induced a stronger increase in neutralizing antibodies against the different VOCs
format Online
Article
Text
id pubmed-9323888
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93238882022-07-27 Characterization of the Antibody and Interferon-Gamma Release Response after a Second COVID-19 Booster Vaccination Grikscheit, Katharina Rabenau, Holger F. Ghodratian, Zahra Widera, Marek Wilhelm, Alexander Toptan Grabmair, Tuna Hoehl, Sebastian Layer, Emily Helfritz, Fabian Ciesek, Sandra Vaccines (Basel) Article The emergence of SARS-CoV-2 Omicron subvariants prompted countries to call for accelerated booster vaccinations to limit disease and transmission. Here, we characterized correlates of protection over time after the second booster or after Omicron BA.1 infection comparing variants of concern (VOCs). Sera from subjects before and two and seven weeks after the second booster or after Omicron infection were examined for the level of Spike receptor-binding-domain (RBD)-specific antibodies. Furthermore, neutralizing antibodies (nABs) were characterized in in vitro neutralization assays comparing the variants of concern Alpha, Beta, Delta, and Omicron BA.1 and BA.2 against the ancestral strain B.1. Here, the second booster resulted in an increase in anti-RBD-IgG-antibodies, remaining nearly constant over time, accompanied by an increase in nABs against B.1 and the VOCs Alpha, Beta, Delta, and Omicron BA.1 and BA.2. However, compared to B.1, the neutralizing capacity against the Omicron subvariants remained low and was limited after the second booster vaccination. This indicates that antibody-mediated protection against infection with this VOC is unlikely, as evidenced by the fact that three individuals of our study cohort became infected with Omicron BA.1 after the second booster. T cell activation was measured by interferon-gamma release assays in a subgroup of subjects and was increased in all subjects tested after the second booster vaccination, correlating with the amount of Spike-specific antibodies. In subjects with Omicron BA.1 breakthrough infection, a significant increase in nABs to all VOCs studied was observed independently of booster vaccinations. Taken together, our data indicate that a second booster or Omicron BA.1 infection mediate a substantial increase in anti-Spike IgG antibodies; however, infection with Omicron BA.1 induced a stronger increase in neutralizing antibodies against the different VOCs MDPI 2022-07-21 /pmc/articles/PMC9323888/ /pubmed/35891326 http://dx.doi.org/10.3390/vaccines10071163 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Grikscheit, Katharina
Rabenau, Holger F.
Ghodratian, Zahra
Widera, Marek
Wilhelm, Alexander
Toptan Grabmair, Tuna
Hoehl, Sebastian
Layer, Emily
Helfritz, Fabian
Ciesek, Sandra
Characterization of the Antibody and Interferon-Gamma Release Response after a Second COVID-19 Booster Vaccination
title Characterization of the Antibody and Interferon-Gamma Release Response after a Second COVID-19 Booster Vaccination
title_full Characterization of the Antibody and Interferon-Gamma Release Response after a Second COVID-19 Booster Vaccination
title_fullStr Characterization of the Antibody and Interferon-Gamma Release Response after a Second COVID-19 Booster Vaccination
title_full_unstemmed Characterization of the Antibody and Interferon-Gamma Release Response after a Second COVID-19 Booster Vaccination
title_short Characterization of the Antibody and Interferon-Gamma Release Response after a Second COVID-19 Booster Vaccination
title_sort characterization of the antibody and interferon-gamma release response after a second covid-19 booster vaccination
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323888/
https://www.ncbi.nlm.nih.gov/pubmed/35891326
http://dx.doi.org/10.3390/vaccines10071163
work_keys_str_mv AT grikscheitkatharina characterizationoftheantibodyandinterferongammareleaseresponseafterasecondcovid19boostervaccination
AT rabenauholgerf characterizationoftheantibodyandinterferongammareleaseresponseafterasecondcovid19boostervaccination
AT ghodratianzahra characterizationoftheantibodyandinterferongammareleaseresponseafterasecondcovid19boostervaccination
AT wideramarek characterizationoftheantibodyandinterferongammareleaseresponseafterasecondcovid19boostervaccination
AT wilhelmalexander characterizationoftheantibodyandinterferongammareleaseresponseafterasecondcovid19boostervaccination
AT toptangrabmairtuna characterizationoftheantibodyandinterferongammareleaseresponseafterasecondcovid19boostervaccination
AT hoehlsebastian characterizationoftheantibodyandinterferongammareleaseresponseafterasecondcovid19boostervaccination
AT layeremily characterizationoftheantibodyandinterferongammareleaseresponseafterasecondcovid19boostervaccination
AT helfritzfabian characterizationoftheantibodyandinterferongammareleaseresponseafterasecondcovid19boostervaccination
AT cieseksandra characterizationoftheantibodyandinterferongammareleaseresponseafterasecondcovid19boostervaccination